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Abstract. 
 
Polyglutamine tract expansion in androgen 
receptor is a recognized cause of spinal and bulbar mus-
cular atrophy (SBMA), an X-linked motor neuronopa-
thy. Similar mutations have been identiﬁed in proteins 
associated with other neurodegenerative diseases. Re-
cent studies have shown that ampliﬁed polyglutamine 
repeat stretches form cellular aggregates that may be 
markers for these neurodegenerative diseases. Here we 
describe conditions that lead to aggregate formation by 
androgen receptor with polyglutamine stretch ampliﬁ-
cation. In transfection experiments, the mutant, com-
pared with the wild-type receptor, was delayed in its cy-
toplasmic–nuclear translocation and formed large 
cytoplasmic aggregates in the presence of androgen. 
The cytoplasmic environment appears crucial for this 
aggregation, since retention of both the wild-type and 
mutant receptors in this cellular compartment by the 
deletion of their nuclear localization signals resulted in 
massive aggregation. Conversely, rapid nuclear trans-
port of both receptors brought about by deletion of 
their ligand binding domains did not result in aggregate 
formation. However, androgen antagonists that altered 
the conformation of the ligand binding domain and 
promoted varying rates of cytoplasmic–nuclear translo-
cation all inhibited aggregate formation. This demon-
strates that in addition to the cytoplasmic localization, a 
distinct contribution of the ligand binding domain of 
the receptor is necessary for the aggregation. The ﬁnd-
ing that antiandrogens inhibit aggregate formation may 
provide the basis for in vivo determination of the role 
of these structures in SBMA.
Key words: cytoplasmic inclusions • spinal and bulbar 
muscular atrophy • antiandrogens • ligand binding do-
main • neurodegenerative disorder
 
Introduction
 
Expansion of CAG trinucleotide repeats encoding poly-
glutamine stretches has been identified as a common
pathogenic mutation for eight neurodegenerative diseases,
including spinal and bulbar muscular atrophy (SBMA),
 
1
 
Huntington disease, dentatorubral-pallidoluysian atrophy
(DRPLA), and five dominantly inherited ataxias-spino-
cerebellar ataxia types 1–3, 6, and 7 (for reviews see Lin et
al., 1999; Perutz, 1999).
Aggregation of the polyglutamine stretches has been
recognized as a common feature of all these CAG repeat–
associated disorders and may act as a marker of the dis-
ease process (Sisodia, 1998). However, a direct link of the
aggregates to the disease process is still elusive. In some
studies, the aggregates were reported as cytotoxic (Ross,
1997). As a result, suppression of aggregation by trans-
glutaminase inhibitors prevented apoptosis induced by
dentatorubral-pallidoluysian atrophy proteins containing
polyglutamine stretch amplifications (Igarashi et al., 1998).
On the other hand, the aggregates have been described as
originating from protein misfolding. The mutant protein
supposedly adopts an altered configuration, leading to
ubiquitination, aggregation, and resistance to proteosomal
degradation. Inhibition of ubiquitination in one study pre-
vented aggregation and accelerated cell death, suggesting
that the aggregates may rather be beneficial and may se-
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Abbreviations used in this paper:
 
 AR, androgen receptor; DIC, differ-
ential interference contrast; DHT, dihydrotestosterone; LBD, ligand
binding domain; NLS, nuclear localization signal(s); SBMA, spinal and
bulbar muscular atrophy. 
The Journal of Cell Biology, Volume 149, 2000 256
 
quester toxic components of the disorder (Saudou et al.,
1998).
Although differences in the alleged function of the ag-
gregates persist, their reported sites of accumulation in the
cell are also not too clear. In Huntington, the aggregates
are present as neuronal intranuclear inclusions (Davies et
al., 1997; Li et al., 1999) or outside the nucleus in the form
of dystrophic neurites and neuropil aggregates (DiFiglia et
al., 1997; Gutekunst et al., 1999). In SCA2 and 6, the mu-
tant proteins accumulated in the cytoplasm, not the nu-
cleus (Huynh et al., 1999; Ishikawa et al., 1999), whereas
aggregates formed by the androgen receptor (AR) in
SBMA are reported both in the cytoplasm and in the nu-
cleus (Stenoien et al., 1999). These different reports have
prompted us to reassess the cellular localization of the AR
isolated from SMBA patients and to define conditions that
lead to the formation of aggregates.
SBMA is a rare motor neuron disorder characterized by
the adult onset of proximal muscle weakness, atrophy, and
fasciculations caused by the degeneration of motor neu-
rons. This disease is slowly progressive and is complicated
by the involvement of bulbar muscles, which may lead to
dysphagia and repeated aspiration pneumonia. Affected
males show signs of androgen insensitivity, including gy-
necomastia, impaired spermatogenesis, reduced fertility,
and testicular atrophy (for reviews see Merry and Fisch-
beck, 1998).
The disease gene was mapped to the proximal long arm
of the X-chromosome specifically to the region where the
AR is localized. The link between SBMA and the AR was
clarified when it was shown that the CAG repeat region in
the AR gene is amplified in SBMA patients (Merry and
Fischbeck, 1998). Beyond the identification of the CAG
trinucleotide repeat, little is known about the molecular
pathogenesis of SBMA, and no effective treatment is
available.
Efforts to create mouse models of SBMA for the study
of the mechanism and treatment of this disorder have
fallen short of reproducing the disease phenotype because
of low levels of expression of the protein (Bingham et al.,
1995). Similarly, cell culture systems in which the tran-
scriptional activity of the mutant receptor was analyzed
did not consistently produce results that could explain the
molecular mechanisms leading to the disease (for review
see Merry and Fischbeck, 1998). Reports that the mutant
AR formed inclusions in cells as other proteins with ampli-
fied polyglutamine stretches (Li et al., 1998; Stenoien et
al., 1999) established aggregation as a common link among
the neurodegenerative diseases caused by polyglutamine
tract amplifications. We have therefore undertaken these
studies to examine the conditions that lead to the forma-
tion of aggregates by the mutant AR.
 
Materials and Methods
 
Cell Culture
 
Simian kidney COS-7 cells were cultured in DME supplemented with
10% FCS at 37
 
8
 
C in an atmosphere of 5% CO
 
2
 
. 24 h before transfection,
the cells were plated onto coverslips in 35-mm tissue culture dishes at a
concentration of 5 
 
3
 
 10
 
4
 
 cells/dish. Transient transfection was carried out
by the Fugene transfection procedure (Boehringer Mannheim) with 1.5
 
m
 
g DNA. 24 h later, the cells were cultured in phenol red–free DME
(GIBCO BRL Life Technology) supplemented with 3% charcoal-treated
FCS for an additional 24 h. Unless otherwise stated, the transfected cells
were treated without hormone (0.1% ethanol as vehicle), with hormone
(vehicle containing 100 nM DHT), or with antihormones for different pe-
riods of time. For the determination of the different stages of cellular lo-
calization of the receptor, the transfected cells were precooled for 5 min
on ice and treated with hormone on ice for 1 h before the final incubation
at 37
 
8
 
C for different periods of time. The cells were then fixed with pre-
chilled methanol for 15 min followed by two washing steps with PBS. The
coverslips were treated at room temperature with PBS containing 0.2%
gelatin, 0.1% Triton X-100 for 45 min and thereafter incubated with poly-
clonal AR44 antibody directed against amino acids 201–222 of the AR (1:
200) for 1 h. The primary antibody was detected with a TRITC-conju-
gated goat anti–rabbit antibody (1:100) (Dianova GmbH).
 
Plasmid Constructs
 
ARQ1, ARQ22, and ARQ77 were obtained by subcloning the corre-
sponding AR sequence (Chamberlain et al., 1994) into the expression vec-
tor pSG5. ARdNLSQ1, ARdNLSQ22, and ARdNLSQ77 were obtained
by PCR-mediated deletion of sequences corresponding to amino acids
614–634 in the ARQ1, ARQ22, and ARQ77 constructs. ARdHBDQ22
and ARdHBDQ77 were generated by the introduction of a stop codon at
amino acid 682 by PCR-mediated mutagenesis.
 
Fluorescence Microscopy
 
Fluorescence microscopy and differential interference contrast (DIC) im-
ages were performed with a Zeiss Axiovert 135 microscope. All image
files were digitally processed for presentation using Adobe Photoshop and
printed using a Tektronix 450 printer.
 
Western Blot
 
Western blot analyses to detect the AR or the polyglutamine stretch were
performed as reported previously (Peterziel et al., 1999).
 
Results and Discussion
 
Nuclear Transport
 
To determine how amplification of the polyglutamine
stretch in the AR affects subcellular localization of this re-
ceptor, the wild-type AR with 22 glutamine residues
(ARQ22) and an AR with glutamine repeat amplification
of 77 residues (ARQ77) were expressed in receptor-nega-
tive COS-7 cells in the absence and presence of the andro-
gen dihydrotestosterone (DHT) (Fig. 1 A). As control, a
receptor construct with deletion of its glutamine repeat se-
quence leaving only one residue (ARQ1) was also ana-
lyzed. Almost equal amounts of the receptors were de-
tected in the transfected cells. In addition, low molecular
weight species containing NH
 
2
 
-terminal forms of the re-
ceptors were detected by the use of an antibody that rec-
ognized NH
 
2
 
-terminal epitope of the AR (Fig. 1 A, arrows
1, 2, and 3 in upper panel). With the use of an antibody
that detects amplified glutamine repeat stretches (Trottier
et al., 1995), we identified in the lane with ARQ77 several
receptor fragments containing the epitope for this anti-
body, including a characteristic 74-kD receptor fragment
initially reported by Butler et al. (1998) (Fig. 1 A, see ar-
row 3 in lower panel). This fragment is supposed to be
generated from a deletion of the hormone binding domain
of ARQ77, and has been proposed as contributing to the
toxicity of the mutant receptor by initiating the expression
of specific genes in the absence of hormone (Butler et al.,
1998).
The subcellular localization of the ARQ1, ARQ22, and 
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ARQ77 was analyzed by fluorescence microscopy in the
absence or after 30 or 90 min treatment with DHT. Five
different phases depicting the cellular localization of the
AR were scored and numerically classified as 0–4. Phase 0
was strictly cytoplasmic, whereas phase 4 showed com-
plete nuclear localization. The phases in between 0 and 4
represented different stages of cytoplasmic–nuclear local-
izations (Fig. 1 B). In three independent experiments in
Figure 1. Subcellular local-
ization of ARs with poly-
glutamine stretch of dif-
ferent lengths. COS-7 cells
were transfected with an
empty expression vector
pSG5 and AR expression
vectors ARQ1, ARQ22, and
ARQ77, and treated with or
without DHT (1027 M) for
0.5 or 1.5 h. (A) Western blot
analysis was performed with
equal amounts of cellular
proteins using the anti-AR
antibody AR44 and an anti-
polyglutamine repeat anti-
body Ic2. The bands marked
1, 2, and 3 in the upper panel
are NH2-terminal AR frag-
ments as they are recognized
by the AR antibody that
detects an NH2-terminal
epitope. In the lower panel,
bands corresponding to
ARQ22 and ARQ77 have
been indicated. Note that the
Ic2 antibody recognizes the
Q77 stretch more effectively
than the Q22 stretch. Also
recognized by the Ic2 anti-
body and indicated as band 3 is a 74-kD NH2-terminal fragment of the AR containing an amplified glutamine stretch. (B) Five different
phases of cellular localization of the AR defined numerically as 0–4. C, cytoplasm; N, nucleus. (C) Shown as bar diagrams are the num-
ber of cells with the transfected receptor at a particular stage of cellular localization in the presence or absence of DHT as determined
by immunofluorescence microscopy. 
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which a total of 
 
.
 
11,000 cells were analyzed, it was in only
a limited number of cells that nuclear localization of the
AR was determined in the absence of hormone. The ma-
jority of cells containing ARQ22 and ARQ77 was scored
between phases 0 and 2 (Fig. 1 C, 
 
2
 
DHT, 0.5 and 1.5 h).
Cells containing ARQ1 had a tendency to migrate into the
nucleus even in the absence of hormone, and were scored
between phases 1 and 3 (Fig. 1 C, 
 
2
 
DHT, 0.5 and 1.5 h). In
the presence of hormone, differences were observed in the
rate of nuclear transport of the receptors. Half an hour af-
ter hormone treatment, ARQ1 was nearly nuclear (phases
3 and 4) (Fig. 1 C, 
 
1
 
DHT, 0.5 h), whereas ARQ22 and
ARQ77 were still between phases 1 and 4 (Fig. 1 C,
 
1
 
DHT, 0.5 h). At 1.5 h, ARQ1 was completely nuclear
(phase 4), whereas the other receptors were distributed
between phases 3 and 4, albeit with the majority at phase 4
(Fig. 1 C, 
 
1
 
DHT, 1.5 h). Thus, the AR with the extended
glutamine stretch less readily entered the nucleus, a trend
that was more pronounced at 0.5 h than at 1.5 h of DHT
treatment. At 1.5 h, when nuclear localization was nearly
complete for ARQ1 and ARQ77, ARQ22 still showed
some cytoplasmic localization. The reason for this is not
quite clear at the moment.
 
Cytoplasmic Aggregates
 
In studies on the nuclear transport of the AR, we noticed
that the receptors appeared in some of the cells as cyto-
plasmic aggregates. For example, 0.5 h after DHT treat-
ment, 5% of the cells transfected with ARQ1 had several
tiny inclusions in the cytoplasm (Fig. 2 A), whereas twice
as many cells (11–13%) containing ARQ22 and ARQ77
Figure 2. Detection of cyto-
plasmic aggregates formed by
the AR constructs ARQ1,
ARQ22, and ARQ77 in
COS-7 cells. COS-7 cells
were transfected with ARQ1,
ARQ22, and ARQ77, treated
with hormones and the cellu-
lar localization of the recep-
tors was determined by fluo-
rescence microscopy. (A–I)
Shown are some of the aggre-
gates formed by these re-
ceptors after 0.5, 1.5, and
3 h. (J–O) A comparison of
the aggregates formed by
ARQ22 and ARQ77 after 3 h
of DHT treatment with the
use of immunoflourescence
experiments (J and M), DIC
(K and N), and an overlay of
the two images (L and O).
The white arrow points to a
single small inclusion and the
black arrow shows aggregates
in the process of being fused.
Bars, 15 mm. 
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exhibited cytoplasmic inclusions (Fig. 2, D and G). At 1.5
and 3 h of hormone treatment, aggregates were no longer
observed in the ARQ1-positive cells (Fig. 2, B and C), but
10% of the cells containing ARQ22 or ARQ77 still pos-
sessed aggregates (Fig. 2, E, F, H, and I). After 24 h of hor-
mone treatment, no aggregates were detected in any of the
cells (data not shown), possibly due to processing by the
molecular chaperones of the cells.
Differences in the structure of the aggregates were evi-
dent. Those formed by ARQ1 were very small and
rounded, whereas those formed by ARQ22 were slightly
larger and quantitatively more than the ARQ1 aggregates
(Fig. 2, A and B). In contrast, cytoplasmic aggregates
formed by ARQ77 were larger and more clustered (Fig. 2,
G–I). The differences in the morphology of the aggregates
formed by ARQ22 and ARQ77 are more clearly demon-
strated in Fig. 2, J–O, along with DIC images. It appeared
that the aggregates formed by ARQ77 fused in time to
form larger aggregates (Fig. 2 N, white and black arrows).
The delayed nuclear transport of ARQ22 and ARQ77
compared with ARQ1 and the fact that those two recep-
tors formed aggregates more efficiently than ARQ1 sug-
gested that the cytoplasmic environment might contribute
to aggregate formation. This notion was not shared by
Perez et al. (1998), who identified the nuclear environ-
ment as the site of aggregation for a SCA3 protein frag-
ment that contained a polyglutamine stretch amplification.
The difference between that report and our study possibly
arose from the use of two different gene products, the AR
and SCA3.
We confirmed that the cytoplasmic environment is the
site for the formation of aggregates by the AR in experi-
ments in which we used ARQ1, ARQ22, and ARQ77 con-
structs lacking their nuclear localization signals (NLS)
Figure 3. Detection of cyto-
plasmic inclusions formed by
ARdNLSQ1, ARdNLSQ22,
and ARdNLSQ77 in COS-7
cells. COS-7 cells were trans-
fected with the indicated re-
ceptor constructs lacking the
NLS, treated with (D–O) or
without (A–C) DHT, and the
cellular localization of the re-
ceptors assessed by fluores-
cence microscopy. Shown are
the different types of aggre-
gates formed as detected by
immunofluorescence micros-
copy, DIC images, and an
overlay of the two pictures.
Bars: 15 mm (A–C); 30 mm
(D–L); and 15 mm (M–O). 
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(ARdNLSQ1, ARdNLSQ22, and ARdNLSQ77). In the
absence of hormone, all three mutant receptors showed a
diffused cytoplasmic expression that was detected by fluo-
rescence microscopy (Fig. 3, A–C). In the presence of
androgen, these receptors formed inclusions that were
permanently cytoplasmic (Figs. 3, D–O). The inclusions
formed by the ARdNLSQ1 and ARdNLSQ22 were
smaller, rounded, and on the whole similar in structure
(Fig. 3, D–I). Thus, the ARQ1 and ARQ22 formed aggre-
gates in the cytoplasm when forced to reside in this cellu-
lar compartment in the presence of hormone. These inclu-
sions were most likely unrelated to the polyglutamine
stretch, as similar structures were observed for both
ARdNLSQ1 and ARdNLSQ22. In contrast, inclusions
formed by ARdNLSQ77 were clearly distinct. They were
larger and possessed a characteristic clustered morphology
(Fig. 3, J–L). In addition, 
 
z
 
10% of the cells transfected
with this mutant receptor formed fibrillary perinuclear
star-like aggregates that were not observed in cells trans-
fected with either the ARdNLSQ1 or ARdNLSQ22 con-
structs (Fig. 3, M–O).
The fibrillary aggregates formed by ARdNLSQ77 were
sometimes as large as 6 
 
m
 
m, but it is uncertain whether
they originated from the large clustered aggregates or
were formed independently. From their structure, they are
reminiscent of scrapie prions and 
 
b
 
-amyloid fibrils in
Alzheimer’s disease (Koo et al., 1999). Upon staining with
Congo red dye, a characteristic red-green birefringence in
polarized light indicative of amyloidogenic inclusions was
not obtained (Glenner, 1980) (data not shown). However,
treatment of the transfected cells with the transglutami-
nase inhibitor cystamine drastically reduced the formation
of the fibrillary aggregates without affecting the formation
of the other aggregates (data not shown). This indicates a
role of a transglutaminase reaction in the formation of the
fibrillary structures. In this connection, it is worth noting
that transglutaminase cross-linking and aggregation of
Huntingtin fragment containing polyglutamine residues
did not stain positive for amyloid (Karpuj et al., 1999), and
filamentous aggregates sensitive to transglutaminase in-
hibitors were identified as pathognomonic of dentatoru-
bral-pallidoluysian atrophy (Igarashi et al., 1998). The
fibrillary structures described in this work may not only be
formed by ARdNLSQ77 but possibly also during the de-
layed transport of the ARQ77 into the nucleus, and may
constitute the toxic component in SBMA.
As the aggregate formation was greatly enhanced by the
delayed nuclear transport of the AR, we performed the
converse experiment in which rapid nuclear transport was
induced to gain further information on aggregate forma-
tion. This was achieved by deletion of the ligand binding
domain (LBD) of ARQ22 and ARQ77. As the LBD is
known to keep the AR in the cytoplasm, these deletion
mutants were constitutively nuclear but they did not form
aggregates, despite the presence of the Q22 and Q77
stretches (Fig. 4). This demonstrates an important role of
the LBD in the formation of aggregates.
To determine the contribution of the LBD to aggregate
formation without necessarily deleting this region of the
receptor, different androgen antagonists were used that
are known to affect the conformation and the rates of cy-
toplasmic–nuclear transport of the receptors (Veldscholte
 
et al. 1992; Kuil and Mulder, 1994; Kuil et al., 1995). In
these experiments, the steroidal antagonist cyproterone
acetate most efficiently promoted nuclear translocation of
the receptors (Fig. 5, A and B), but not the nonsteroidal
antagonists hydroxyflutamide or casodex (Fig. 5, I–L).
Nonetheless, hydroxyflutamide and casodex did not in-
duce aggregate formation by the wild-type ARQ22 and
ARQ77 or by the NLS-defective mutant ARdNLSQ77
(Fig. 5, I–N). Cyproterone acetate, on the other hand, pro-
duced very tiny inclusions (Fig. 5, E and F) but these were
nowhere near the large aggregates produced by DHT
(Fig. 5, C and D). The difference in the action of the antag-
onists may be related to their structure and to their affinity
to the LBD. Cyproterone acetate, a steroidal compound,
binds slightly better to the AR than the nonsteroidal an-
tagonists, hydroxyflutamide and casodex (Culig et al.,
1993). In competition assays, the clustered aggregates and
fibrillary depositions formed by the ARdNLSQ77 in the
presence of DHT (Fig. 5, C and D) were drastically re-
duced by cyproterone acetate as well as by hydroxyfluta-
mide and casodex (Fig. 5, G and H; data not shown). The
biological significance of the destruction of aggregate for-
mation by antiandrogens and the role of the cytoplasmic
aggregation in SBMA in general are to be investigated in
the future in transgenic mouse models. In this connection,
cytoplasmic aggregate formation brought about by the
ARdNLSQ77 will be targeted to specific areas of the brain
of the mouse to find out whether they give rise to the neu-
rodegenerative disorders described in SBMA.
Taken together, our results show that although cytoplas-
mic localization of the AR with polyglutamine stretch am-
Figure 4. Androgen receptor lacking the LBD does not form ag-
gregates. COS-7 cells were transfected with ARQ22 and ARQ77
lacking the LBD (ARdHBDQ22, ARdHBDQ77) and cellular lo-
calization of the receptor was determined by fluorescence micros-
copy. 
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plification may play a crucial role in the formation of ag-
gregates, the LBD and the type of ligand bound are
essential in this process. This latter point is important in
view of the fact that, in the past, androgens were used for
the treatment of SBMA, but rather unsuccessfully (Danek
et al., 1994; Neuschmid-Kaspar et al., 1996). The ineffec-
tiveness of the androgen therapy could be mechanistically
accounted for by the induction of aggregate formation by
these ligands. Our findings that antiandrogens inhibited
 
aggregate formation would therefore form a useful start-
ing point for determining the contribution of these struc-
tures to SBMA, and could provide the basis for a possible
therapeutic intervention of this disorder.
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